Methods for treating cholestasis
Provided herein are methods for treating cholestasis in a subject having a liver disease. The method includes administering to the subject an Apical Sodium-dependent Bile Acid Transporter (ASBTI). More specifically, the present invention relates to methods for treating cholestasis in a subject where the method includes administering an ASBTI to a subject at a dose of at least 10 μg/kg/day.
1. A method for treating Alagille Syndrome (ALGS) in a subject in need of such treatment comprising administering to the subject maralixibat in an amount of from 360 μg/kg/day to 880 μg/kg/day.
2. The method of claim 1 , wherein maralixibat is administered in an amount of 360 μg/kg/day to 440 μg/kg/day.
3. The method of claim 1 , wherein maralixibat is administered once daily (QD).
4. The method of claim 1 , wherein maralixibat is administered twice daily (BID).
5. The method of claim 1 , wherein maralixibat is administered for at least 18 weeks.
6. The method of claim 1 , wherein maralixibat is administered for at least 2 years.
7. The method of claim 1 , wherein maralixibat is administered for at least 3 years.
8. The method of claim 1 , wherein the subject exhibits below normal height or weight prior to the administration of maralixibat.
9. The method of claim 1 , wherein the subject experiences pruritus prior to the administration of maralixibat.
10. The method of claim 1 , wherein the subject is a pediatric subject.
11. The method of claim 1 , wherein the subject is at least 1 year of age.
12. The method of claim 1 , wherein maralixibat is administered prior to ingestion of food.
13. The method of claim 1 , wherein maralixibat is administered orally.